Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Jazz Pharmaceuticals Announces Third Quarter 2015 Financial Results

      Third Quarter 2015 Revenues Increase 11 Percent to $341 Million

      Strong Top-Line Growth Driven by Xyrem and Erwinaze Sales


      News provided by

      Jazz Pharmaceuticals

      Nov 09, 2015, 04:05 ET

      Share this article

      Share this article


      Jazz Pharmaceuticals Logo
      Jazz Pharmaceuticals Logo

      DUBLIN, Nov. 9, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2015 and updated financial guidance for 2015.

      "During the quarter, we remained focused on our mission of delivering important and meaningful products to patients. We are pleased that we have received FDA Priority Review status on our defibrotide NDA, an important step toward our objective to bring defibrotide to patients in the U.S. for the treatment of hepatic veno-occlusive disease with evidence of multi-organ dysfunction, a rare and often fatal complication of hematopoietic stem cell transplantation," said Bruce C. Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. "We also advanced our research and development pipeline, implemented our approved Xyrem REMS, grew key product sales, and remain well-positioned to further diversify and expand our product portfolio through our corporate development efforts."

      Adjusted net income attributable to Jazz Pharmaceuticals plc for the third quarter of 2015 was $159.3 million, or $2.52 per diluted share, compared to $143.9 million, or $2.30 per diluted share, for the third quarter of 2014.

      GAAP net income attributable to Jazz Pharmaceuticals plc for the third quarter of 2015 was $88.0 million, or $1.39 per diluted share, compared to $25.8 million, or $0.41 per diluted share, for the third quarter of 2014. Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included in this press release.

      Third Quarter 2015 Revenues and Product Sales

      Total revenues for the third quarter of 2015 were $340.9 million, an increase of 11% over total revenues of $306.6 million for the third quarter of 2014. The increase in total revenues was driven by higher net product sales of Xyrem® (sodium oxybate) oral solution and Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi). Total revenues include net product sales, royalties and contract revenues.

      Net product sales for the third quarter of 2015 were as follows:

      • Xyrem: Xyrem net sales increased by 19% to $242.9 million in the third quarter of 2015 compared to $204.3 million in the third quarter of 2014. During the third quarter of 2015, the average number of active Xyrem patients in the U.S. was approximately 12,450.
      • Erwinaze/Erwinase: Erwinaze/Erwinase net sales increased by 8% to $56.3 million in the third quarter of 2015 compared to $52.1 million in the third quarter of 2014.
      • Defitelio® (defibrotide): Defitelio/defibrotide net sales increased to $19.6 million in the third quarter of 2015 compared to $18.9 million in the third quarter of 2014. Product volume was in line with expectations, but sales were impacted by unfavorable foreign currency exchange movements.
      • Prialt® (ziconotide) intrathecal infusion: Prialt net sales were $6.0 million in the third quarter of 2015 compared to $6.3 million in the third quarter of 2014.
      • Psychiatry products: Net sales of the company's psychiatry products were $9.9 million in the third quarter of 2015 compared to $10.8 million in the third quarter of 2014.
      • Other: Net sales of other products in the third quarter of 2015 were $3.9 million compared to $11.9 million in the third quarter of 2014. In March 2015, the company completed the sale of certain products and the related business that the company acquired as part of the acquisition of EUSA Pharma Inc. in 2012.

      Tables showing actual net product sales for the three and nine months ended September 30, 2015 and 2014 and pro forma net product sales for the nine months ended September 30, 2014 are included in this press release.

      Operating Expenses and Other

      Operating expenses for the third quarter of 2015 were $209.3 million compared to $248.5 million for the third quarter of 2014. Operating expenses changed over the prior year period primarily due to the following:

      • Cost of product sales for the third quarter of 2015 was $28.4 million compared to $27.0 million for the same period in 2014. Gross margin for the third quarter of 2015 was 91.6% compared to 91.1% for the same period in 2014.
      • Selling, general and administrative (SG&A) expenses for the third quarter of 2015 on a GAAP basis were $104.0 million compared to $93.5 million for the same period in 2014. Adjusted SG&A expenses for the third quarter of 2015 were $84.5 million, or 25% of total revenues, compared to $78.7 million, or 26% of total revenues, for the same period in 2014. The increase in both GAAP and adjusted SG&A expenses was primarily due to higher headcount and other expenses resulting from the expansion of the company's business.
      • Research and development (R&D) expenses for the third quarter of 2015 were $50.8 million on a GAAP basis compared to $22.4 million for the same period in 2014. The increase resulted primarily from a $25.0 million milestone payment that was triggered by the acceptance for filing by the FDA of the first new drug application (NDA) for defibrotide. The milestone was paid in October 2015. Adjusted R&D expenses for the third quarter of 2015 were $23.0 million, or 7% of total revenues, compared to $18.4 million, or 6% of total revenues, for the same period in 2014. Both GAAP and adjusted R&D expenses increased due to higher clinical studies and outside services costs for the development of new product candidates and line extensions for the company's existing products.
      • Acquired in-process research and development expenses of $75.0 million incurred during the third quarter of 2014 related to an upfront payment made for rights to defibrotide in the Americas.

      Net interest expense for the third quarter of 2015 was $12.7 million compared to $14.5 million for the third quarter of 2014. In June 2015, the company refinanced its existing term loans and revolving credit facility and obtained a more favorable interest rate, which reduced interest expense.

      As of September 30, 2015, cash and cash equivalents were $998.9 million, and the outstanding principal balance of the company's long-term debt was $1.4 billion. Cash and cash equivalents increased from December 31, 2014 primarily due to cash generated by the business. In October 2015, the company repaid its revolving credit facility balance of $80.0 million.

      During the nine months ended September 30, 2015, the company repurchased 0.1 million ordinary shares for $21.3 million at an average cost of $172.43 per ordinary share under its $200 million share repurchase program announced in 2013. The company completed this share repurchase program in August 2015.

      Recent Developments

      On November 5, 2015, the company's board of directors authorized a new share repurchase program pursuant to which the company is authorized to repurchase a number of ordinary shares having an aggregate purchase price of up to $300 million, exclusive of any brokerage commissions. Under this program, which has no expiration date, the company may repurchase ordinary shares from time to time on the open market. The timing and amount of repurchases will be at management's discretion and will depend on a variety of factors, including the price of the company's ordinary shares, alternative investment opportunities, restrictions under the company's credit agreement, corporate and regulatory requirements and market conditions. The share repurchase program may be modified, suspended or discontinued at any time without prior notice.

      2015 Financial Guidance 

      Jazz Pharmaceuticals is updating its full year 2015 financial guidance, which is as follows:



      Revenues

      $1,320-$1,340 million

      Total net product sales

      $1,313-$1,332 million

      -Xyrem net sales

      $950-$965 million

      -Erwinaze/Erwinase net sales

      $200-$210 million

      -Defitelio/defibrotide net sales

      $70-$75 million

      Adjusted gross margin %1, 5

      92-93%

      Adjusted SG&A expenses2, 5

      $355-$365 million

      Adjusted R&D expenses3, 5

      $95-$105 million

      Adjusted interest expense4,5

      $34-$36 million

      GAAP net income attributable to Jazz Pharmaceuticals plc per diluted share

      $5.42-$5.63

      Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc per diluted share5

      $9.45-$9.60


      _____________________________



      1.

      Excludes $3 million of share-based compensation expense from estimated GAAP gross margin of 92-93%.

      2.

      Excludes $74-$77 million of share-based compensation expense and $1-$2 million of transaction, integration and restructuring costs from estimated GAAP SG&A expenses of $430-$444 million.

      3.

      Excludes a $25 million milestone payment made in October 2015 in connection with the acceptance for filing by the FDA of the first NDA for defibrotide for VOD and $13-$15 million of share-based compensation expense from estimated GAAP R&D expenses of $133-$145 million.

      4.

      Excludes non-cash interest expense of $22-$25 million from estimated GAAP interest expense of $56-$61 million.

      5.

      See "Non-GAAP Financial Measures" below. Reconciliations of non-GAAP adjusted guidance measures are included above and in the tables accompanying this press release.

      Conference Call Details

      Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. EST (9:30 p.m. GMT) to provide a business and financial update and discuss its 2015 third quarter results and 2015 financial guidance. The live webcast may be accessed from the Investors & Media section of the company's website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing +1 800 706 7741 in the U.S., or +1 617 614 3471 outside the U.S., and entering passcode 42845707.

      A replay of the conference call will be available through November 16, 2015 by dialing +1 888 286 8010 in the U.S., or +1 617 801 6888 outside the U.S., and entering passcode 49857476. An archived version of the webcast will be available for at least one week in the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  

      About Jazz Pharmaceuticals plc

      Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution and Erwinaze® (asparaginase Erwinia chrysanthemi) in the U.S., and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S. For more information, please visit www.jazzpharmaceuticals.com.

      Non-GAAP Financial Measures

      To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this press release and the accompanying tables. The company believes that each of these non-GAAP financial measures is helpful in understanding its past financial performance and potential future results, particularly in light of the effect of various acquisition and divestiture transactions effected by the company. They are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with the consolidated financial statements prepared in accordance with GAAP. Jazz Pharmaceuticals' management regularly uses these supplemental non-GAAP financial measures internally to understand, manage and evaluate its business and make operating decisions. Compensation of executives is based in part on the performance of the company's business based on certain of these non-GAAP financial measures. In addition, Jazz Pharmaceuticals believes that the presentation of these non-GAAP financial measures is useful to investors because it enhances the ability of investors to compare the company's results from period to period and allows for greater transparency with respect to key financial metrics the company uses in making operating decisions, and also because the company's investors and analysts regularly use them to model and track the company's financial performance.

      Investors should note that these non-GAAP financial measures are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the company's results of operations as determined in accordance with GAAP. Investors should also note that these non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. In this regard, commencing with the company's presentation of 2015 non-GAAP financial measures, the company no longer includes an adjustment for depreciation expense in its non-GAAP adjusted financial measures. Likewise, for purposes of comparability, non-GAAP adjusted financial measures for 2014 included in this press release and accompanying tables do not include an adjustment for depreciation expense. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the company's competitors and other companies.

      As used in this press release, (i) the historical adjusted net income measures attributable to Jazz Pharmaceuticals plc (and the related per share measures) exclude from GAAP reported net income (loss) attributable to Jazz Pharmaceuticals plc (and the related per share measures), as applicable, intangible asset amortization, share-based compensation expense, upfront and milestone payments, restructuring charges, transaction and integration costs, impairment charges, acquisition accounting inventory fair value step-up adjustments, non-cash interest expense and loss on extinguishment and modification of debt; adjust the income tax provision to the estimated amount of taxes that are payable in cash; and adjust for the amount attributable to noncontrolling interests; (ii) the historical adjusted SG&A expense measures exclude from GAAP SG&A expenses, as applicable, share-based compensation expense, restructuring charges and transaction and integration costs; (iii) the historical adjusted R&D expense measures exclude from GAAP R&D expenses the defibrotide NDA acceptance milestone, share-based compensation expense and transaction and integration costs; (iv) the adjusted net income attributable to Jazz Pharmaceuticals plc (and the related per share measures) guidance exclude from estimated GAAP net income attributable to Jazz Pharmaceuticals plc (and the related per share measures) intangible asset amortization, share-based compensation expense, upfront and milestone payments, transaction, integration and restructuring costs, non-cash interest expense and loss on extinguishment and modification of debt; and adjust the income tax provision to the estimated amount of taxes that are payable in cash; (v) the adjusted gross margin percentage guidance excludes from estimated GAAP gross margin percentage share-based compensation expense; (vi) the adjusted SG&A expenses guidance excludes from estimated GAAP SG&A expenses share-based compensation expense and transaction, integration and restructuring costs; (vii) the adjusted R&D expenses guidance excludes from estimated GAAP R&D expenses the defibrotide NDA acceptance milestone and share-based compensation expense; and (viii) the adjusted interest expense guidance excludes from estimated GAAP interest expense non-cash interest expense.

      "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

      This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' future financial or operating results, including its 2015 financial guidance, diversification and expansion of the company's product portfolio and other statements that are not historical facts. These forward-looking statements are based on the company's current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with maintaining or increasing sales of and revenue from Xyrem, such as the potential introduction of generic competition or other sodium oxybate products that compete with Xyrem; the significant regulatory restrictions and requirements applicable to Xyrem and potential impact of changes to these restrictions and requirements, as well as the company's ongoing patent litigation and related proceedings, including the timing of related events; the company's ability to effectively commercialize its other lead marketed products; the company's ability to effectively commercialize its product candidates (including defibrotide in the U.S. if the company's NDA is approved by the FDA), including the need to establish pricing and reimbursement support; the company's ability to protect and enhance the company's intellectual property rights; delays or problems in the supply or manufacture of the company's products and product candidates, which could impact the company's ability to meet commercial demand or conduct or complete clinical trials; obtaining and maintaining appropriate pricing and reimbursement for the company's products in an increasingly challenging environment; the challenges of compliance with the requirements of U.S. and non-U.S. regulatory agencies; the challenges of achieving and maintaining commercial success of the company's products; the risks and costs associated with business combination or product or product candidate acquisition transactions; the difficulty and uncertainty of pharmaceutical product development, including the timing thereof, and the uncertainty of clinical success; the inherent uncertainty associated with the regulatory approval process, including the risk that the company may be unable to obtain regulatory approval for defibrotide in the U.S. in a timely manner or at all; the company's potential inability to identify and acquire, in-license or develop additional products or product candidates to grow its business; possible restrictions on the company's ability and flexibility to pursue certain future corporate development and other opportunities as a result of its substantial outstanding debt obligations; the uncertainty of expected future financial performance and results; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 and future filings and reports by the company, including the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the company on its website or otherwise. The company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

      JAZZ PHARMACEUTICALS PLC

      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

      (In thousands, except per share amounts)

      (Unaudited)


















      Three Months Ended
      September 30,


      Nine Months Ended
      September 30,


      2015


      2014


      2015


      2014

      Revenues:








      Product sales, net

      $

      338,754



      $

      304,407



      $

      977,895



      $

      838,493


      Royalties and contract revenues

      2,118



      2,177



      6,027



      6,240


      Total revenues

      340,872



      306,584



      983,922



      844,733


      Operating expenses:








      Cost of product sales (excluding amortization and impairment of intangible assets)

      28,385



      26,994



      78,496



      88,610


      Selling, general and administrative

      104,044



      93,501



      323,564



      300,420


      Research and development

      50,784



      22,423



      105,798



      60,622


      Acquired in-process research and development

      —



      75,000



      —



      202,000


      Intangible asset amortization

      26,127



      30,630



      74,472



      94,607


      Impairment charges

      —



      —



      —



      32,806


      Total operating expenses

      209,340



      248,548



      582,330



      779,065


      Income from operations

      131,532



      58,036



      401,592



      65,668


      Interest expense, net

      (12,650)



      (14,530)



      (44,707)



      (36,035)


      Foreign currency gain (loss)

      (977)



      6,483



      (646)



      6,680


      Loss on extinguishment and modification of debt

      —



      —



      (16,815)



      —


      Income before income tax provision

      117,905



      49,989



      339,424



      36,313


      Income tax provision

      29,945



      24,221



      92,651



      60,598


      Net income (loss)

      87,960



      25,768



      246,773



      (24,285)


      Net income (loss) attributable to noncontrolling interests, net of tax

      —



      2



      (1)



      (1,060)


      Net income (loss) attributable to Jazz Pharmaceuticals plc

      $

      87,960



      $

      25,766



      $

      246,774



      $

      (23,225)










      Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share:








      Basic

      $

      1.43



      $

      0.43



      $

      4.04



      $

      (0.39)


      Diluted

      $

      1.39



      $

      0.41



      $

      3.91



      $

      (0.39)


      Weighted-average ordinary shares used in per share calculation - basic

      61,435



      60,305



      61,145



      59,457


      Weighted-average ordinary shares used in per share calculation - diluted

      63,154



      62,680



      63,072



      59,457


      JAZZ PHARMACEUTICALS PLC

      SUMMARY OF PRODUCT SALES, NET

      (In thousands)

      (Unaudited)


















      Three Months Ended
      September 30,


      Nine Months Ended
      September 30,


      2015


      2014


      2015


      2014

      Xyrem

      $

      242,899



      $

      204,337



      $

      703,435



      $

      556,081


      Erwinaze/Erwinase

      56,317



      52,121



      152,821



      146,910


      Defitelio/defibrotide

      19,639



      18,892



      52,259



      51,345


      Prialt

      6,042



      6,282



      19,944



      16,422


      Psychiatry

      9,910



      10,833



      28,375



      32,431


      Other

      3,947



      11,942



      21,061



      35,304


      Total net product sales

      $

      338,754



      $

      304,407



      $

      977,895



      $

      838,493


      The following unaudited pro forma information represents net product sales for the nine months ended September 30, 2014 as if the company's acquisition of Gentium S.p.A. had been completed on January 1, 2014:

      SUMMARY OF PRODUCT SALES, NET (PRO FORMA)

      (In thousands)

      (Unaudited)






      Nine Months
      Ended
      September 30,
      2014

      Xyrem

      $

      556,081


      Erwinaze/Erwinase

      146,910


      Defitelio/defibrotide

      54,242


      Prialt

      16,422


      Psychiatry

      32,431


      Other

      35,710


      Total pro forma net product sales

      $

      841,796


      JAZZ PHARMACEUTICALS PLC

      CONDENSED CONSOLIDATED BALANCE SHEETS

      (In thousands)

      (Unaudited)











      September 30,
      2015


      December 31,
      2014

      ASSETS




      Current assets:




      Cash and cash equivalents

      $

      998,859



      $

      684,042


      Accounts receivable, net of allowances

      195,816



      186,371


      Inventories

      30,018



      30,037


      Prepaid expenses

      21,275



      12,800


      Deferred tax assets, net

      50,006



      48,440


      Other current assets

      18,969



      21,322


      Assets held for sale

      —



      32,833


      Total current assets

      1,314,943



      1,015,845


      Property and equipment, net

      83,452



      58,363


      Intangible assets, net

      1,270,777



      1,437,435


      Goodwill

      669,029



      702,713


      Deferred tax assets, net, non-current

      76,391



      75,494


      Deferred financing costs

      24,315



      33,174


      Other non-current assets

      25,393



      15,931


      Total assets

      $

      3,464,300



      $

      3,338,955


      LIABILITIES AND SHAREHOLDERS' EQUITY




      Current liabilities:




      Accounts payable

      $

      29,124



      $

      25,126


      Accrued liabilities

      166,375



      164,091


      Current portion of long-term debt

      117,589



      9,428


      Income taxes payable

      16,357



      7,588


      Deferred tax liability, net

      9,417



      9,430


      Deferred revenue

      1,330



      1,138


      Total current liabilities

      340,192



      216,801


      Deferred revenue, non-current

      3,646



      4,499


      Long-term debt, less current portion

      1,172,103



      1,333,000


      Deferred tax liability, net, non-current

      325,216



      375,054


      Other non-current liabilities

      59,666



      38,393


      Total Jazz Pharmaceuticals plc shareholders' equity

      1,563,463



      1,371,144


      Noncontrolling interests

      14



      64


      Total liabilities and shareholders' equity

      $

      3,464,300



      $

      3,338,955


      JAZZ PHARMACEUTICALS PLC

      RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

      (In thousands, except per share amounts)

      (Unaudited)


















      Three Months Ended
      September 30,


      Nine Months Ended
      September 30,


      2015


      2014 *


      2015


      2014 *

      GAAP reported net income (loss) attributable to Jazz Pharmaceuticals plc

      $

      87,960



      $

      25,766



      $

      246,774



      $

      (23,225)


      Intangible asset amortization

      26,127



      30,630



      74,472



      94,607


      Share-based compensation expense

      23,114



      18,251



      67,233



      50,618


      Upfront and milestone payments

      25,000



      75,000



      25,000



      202,000


      Restructuring charges

      —



      —



      553



      —


      Transaction and integration costs

      —



      878



      155



      23,518


      Impairment charges

      —



      —



      —



      32,806


      Acquisition accounting inventory fair value step-up adjustments

      —



      —



      —



      10,477


      Non-cash interest expense

      5,300



      4,065



      17,348



      7,603


      Loss on extinguishment and modification of debt

      —



      —



      16,815



      —


      Income tax adjustments

      (8,162)



      (10,649)



      (11,762)



      (27,493)


      Adjustments for amount attributable to noncontrolling interests

      —



      (2)



      (2)



      (1,504)


      Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc

      $

      159,339



      $

      143,939



      $

      436,586



      $

      369,407










      GAAP reported net income (loss) attributable to Jazz Pharmaceuticals plc per diluted share

      $

      1.39



      $

      0.41



      $

      3.91



      $

      (0.39)


      Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc per diluted share

      $

      2.52



      $

      2.30



      $

      6.92



      $

      5.91


      Weighted-average ordinary shares used in diluted per share calculation - GAAP

      63,154



      62,680



      63,072



      59,457


      Weighted-average ordinary shares used in diluted per share calculation - non-GAAP

      63,154



      62,680



      63,072



      62,532



      _____________________________

       * For purposes of comparability with its 2015 presentation, the company's non-GAAP adjusted financial measures for 2014 do not include an adjustment for depreciation expense. See "Non-GAAP Financial Measures" in the accompanying press release for additional information.

      JAZZ PHARMACEUTICALS PLC

      RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

      CERTAIN LINE ITEMS AND OTHER INFORMATION

      (In thousands, except per share amounts and percentages)

      (Unaudited)


























      Three Months Ended


      September 30, 2015


      September 30, 2014


      GAAP Reported


      Adjustments


      Non-GAAP Adjusted *


      GAAP Reported


      Adjustments


      Non-GAAP Adjusted *

      Total revenues

      $

      340,872



      $

      —



      $

      340,872



      $

      306,584



      $

      —



      $

      306,584


      Cost of product sales (excluding amortization and impairment of intangible assets)

      28,385



      (786)


      (a)

      27,599



      26,994



      (240)


      (a)

      26,754


      Selling, general and administrative

      104,044



      (19,542)


      (b)

      84,502



      93,501



      (14,834)


      (b)

      78,667


      Research and development

      50,784



      (27,786)


      (c)

      22,998



      22,423



      (4,055)


      (c)

      18,368


      Acquired in-process research and development

      —



      —



      —



      75,000



      (75,000)



      —


      Intangible asset amortization

      26,127



      (26,127)



      —



      30,630



      (30,630)



      —


      Interest expense, net

      12,650



      (5,300)


      (d)

      7,350



      14,530



      (4,065)


      (d)

      10,465


      Foreign currency (gain) loss

      977



      —



      977



      (6,483)



      —



      (6,483)


      Income before income tax provision

      117,905



      79,541


      (e)

      197,446



      49,989



      128,824


      (e)

      178,813


      Income tax provision

      29,945



      8,162


      (f)

      38,107



      24,221



      10,649


      (f)

      34,870


      Effective tax rate (g)

      25.4

      %




      19.3

      %


      48.5

      %

      (o)



      19.5

      %

      Net income

      87,960



      71,379


      (h)

      159,339



      25,768



      118,175


      (h)

      143,943


      Net income attributable to noncontrolling interests, net of tax

      —



      —



      —



      2



      2


      (i)

      4


      Net income attributable to Jazz Pharmaceuticals plc

      $

      87,960



      $

      71,379



      $

      159,339



      $

      25,766



      $

      118,173


      (j)

      $

      143,939


      Net income attributable to Jazz Pharmaceuticals plc per diluted share

      $

      1.39





      $

      2.52



      $

      0.41





      $

      2.30


      JAZZ PHARMACEUTICALS PLC

      RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

      CERTAIN LINE ITEMS AND OTHER INFORMATION

      (In thousands, except per share amounts and percentages)

      (Unaudited)


























      Nine Months Ended


      September 30, 2015


      September 30, 2014


      GAAP Reported


      Adjustments


      Non-GAAP Adjusted *


      GAAP Reported


      Adjustments


      Non-GAAP Adjusted *

      Total revenues

      $

      983,922



      $

      —



      $

      983,922



      $

      844,733



      $

      —



      $

      844,733


      Cost of product sales (excluding amortization and impairment of intangible assets)

      78,496



      (2,253)


      (k)

      76,243



      88,610



      (12,182)


      (k)

      76,428


      Selling, general and administrative

      323,564



      (55,551)


      (l)

      268,013



      300,420



      (62,445)


      (l)

      237,975


      Research and development

      105,798



      (35,137)


      (m)

      70,661



      60,622



      (9,986)


      (m)

      50,636


      Acquired in-process research and development

      —



      —



      —



      202,000



      (202,000)



      —


      Intangible asset amortization

      74,472



      (74,472)



      —



      94,607



      (94,607)



      —


      Impairment charges

      —



      —



      —



      32,806



      (32,806)



      —


      Interest expense, net

      44,707



      (17,348)


      (d)

      27,359



      36,035



      (7,603)


      (d)

      28,432


      Foreign currency (gain) loss

      646



      —



      646



      (6,680)



      —



      (6,680)


      Loss on extinguishment and modification of debt

      16,815



      (16,815)



      —



      —



      —



      —


      Income before income tax provision

      339,424



      201,576


      (n)

      541,000



      36,313



      421,629


      (n)

      457,942


      Income tax provision

      92,651



      11,762


      (f)

      104,413



      60,598



      27,493


      (f)

      88,091


      Effective tax rate (g)

      27.3

      %




      19.3

      %


      166.9

      %

      (o)



      19.2

      %

      Net income (loss)

      246,773



      189,814


      (p)

      436,587



      (24,285)



      394,136


      (p)

      369,851


      Net income attributable to noncontrolling interests, net of tax

      (1)



      2


      (i)

      1



      (1,060)



      1,504


      (i)

      444


      Net income (loss) attributable to Jazz Pharmaceuticals plc

      $

      246,774



      $

      189,812


      (q)

      $

      436,586



      $

      (23,225)



      $

      392,632


      (q)

      $

      369,407


      Net income (loss) attributable to Jazz Pharmaceuticals plc per diluted share

      $

      3.91





      $

      6.92



      $

      (0.39)





      $

      5.91


      JAZZ PHARMACEUTICALS PLC

      RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

      CERTAIN LINE ITEMS AND OTHER INFORMATION

      (In thousands)

      (Unaudited)


      *

      Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc and its line item components and related non-GAAP adjusted financial measures shown in the tables above are not meant to be considered in isolation or as a substitute for comparable GAAP reported measures, and should be read in conjunction with the condensed consolidated financial statements prepared in accordance with GAAP. The company believes that each of these non-GAAP adjusted financial measures is helpful in understanding its past financial performance and potential future results, particularly in light of the effect of various acquisition and divestiture transactions effected by the company. Company management regularly uses these supplemental non-GAAP financial measures internally to understand, manage and evaluate its business and make operating decisions. Compensation of executives is based in part on the performance of the company's business based on certain of these non-GAAP financial measures. In addition, the company believes that the presentation of these non-GAAP adjusted financial measures is useful to investors because it enhances the ability of investors to compare its results from period to period and allows for greater transparency with respect to key financial metrics the company uses in making operating decisions, and also because the company's investors and analysts regularly use them to model and track the company's financial performance. Specifically, the company believes that each of these non-GAAP adjusted financial measures provides useful information to management, investors and analysts by excluding, as applicable, intangible asset amortization, share-based compensation expense, upfront and milestone payments, restructuring charges, transaction and integration costs, impairment charges, acquisition accounting inventory fair value step-up adjustments, non-cash interest expense and loss on extinguishment and modification of debt that may not be indicative of the company's core operating results and business outlook, and by including adjustments to convert the income tax provision to the estimated amount of taxes that are payable in cash and adjustments for the amount attributable to noncontrolling interests. Investors should note that these non-GAAP adjusted financial measures are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the company's results of operations as determined in accordance with GAAP. Investors should also note that these non-GAAP adjusted financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP adjusted financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP adjusted financial measures. In this regard, commencing with the company's presentation of 2015 non-GAAP financial measures, the company no longer includes an adjustment for depreciation expense in its non-GAAP adjusted financial measures. For purposes of comparability, non-GAAP adjusted financial measures for 2014 included herein do not include an adjustment for depreciation expense. In addition, because of the non-standardized definitions of non-GAAP adjusted financial measures, the non-GAAP adjusted financial measures appearing herein may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the company's competitors and other companies.



      Explanation of Adjustments and Certain Line Items:



      (a)

      Share-based compensation expense of $786 and $240 for the three months ended September 30, 2015 and 2014, respectively.



      (b)

      Share-based compensation expense of $19,542 and $14,834 for the three months ended September 30, 2015 and 2014, respectively.



      (c)

      Milestone of $25,000 and $0, share-based compensation expense of $2,786 and $3,177 and transaction and integration costs of $0 and $878 for the three months ended September 30, 2015 and 2014, respectively.



      (d)

      Non-cash interest expense associated with debt discount and debt issuance costs for the respective three- and nine-month period.



      (e)

      Sum of adjustments (a) through (d) plus the adjustments for acquired in-process research and development and intangible asset amortization for the respective three-month period.



      (f)

      Adjustments to convert the income tax provision to the estimated amount of taxes that are payable in cash for the respective three- and nine-month periods.



      (g)

      Income tax provision divided by income before income tax provision for the respective three- and nine-month periods.



      (h)

      Net of adjustments (e) and (f) for the respective three-month period.



      (i)

      Adjustments for amount attributable to noncontrolling interests for the respective three- and nine-month periods.



      (j)

      Net of adjustments (h) and (i) for the respective three-month period.



      (k)

      Share-based compensation expense of $2,253 and $1,705 and acquisition accounting inventory fair value step-up adjustments of $0 and $10,477 for the nine months ended September 30, 2015 and 2014, respectively.



      (l)

      Share-based compensation expense of $54,843 and $40,051, restructuring charges of $553 and $0 and transaction and integration costs of $155 and $22,394 for the nine months ended September 30, 2015 and 2014, respectively.



      (m)

      Milestone of $25,000 and $0, share-based compensation expense of $10,137 and $8,862 and transaction and integration costs of $0 and $1,124 for the nine months ended September 30, 2015 and 2014, respectively.



      (n)

      Sum of adjustments (k), (l), (m) and (d) plus the adjustments for acquired in-process research and development expenses, intangible asset amortization, impairment charges and loss on extinguishment and modification of debt, as applicable, for the respective nine-month period.



      (o) 

      After adjusting the income before income tax provision for the three months ended September 30, 2014 by excluding an upfront payment of $75,000 for rights to defibrotide in the Americas, the company would have had income before income tax provision of $124,989, resulting in an effective tax rate of 19.4% for the three months ended September 30, 2014 based on the income tax provision of $24,221. After adjusting the income before income tax provision for the nine months ended September 30, 2014 by excluding a total of $202,000 in upfront and milestone payments for rights to JZP-110 and to defibrotide in the Americas, the company would have had income before income tax provision of $238,313, resulting in an effective tax rate of 25.4% for the nine months ended September 30, 2014 based on the income tax provision of $60,598.



      (p)

      Net of adjustments (n) and (f) for the respective nine-month period.



      (q)

      Net of adjustments (p) and (i) for the respective nine-month period.

      JAZZ PHARMACEUTICALS PLC

      RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED 2015 GUIDANCE

      (In millions, except per share amounts)

      (Unaudited)



      GAAP net income attributable to Jazz Pharmaceuticals plc

      $341 - $355

      Intangible asset amortization

      95 - 100

      Share-based compensation expense

      90 - 95

      Upfront and milestone payments

      25

      Transaction, integration and restructuring costs

      1 - 2

      Non-cash interest expense

      22 - 25

      Loss on extinguishment and modification of debt

      17

      Income tax adjustments

      (10) - 0

      Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc

      $595 - $605



      GAAP net income attributable to Jazz Pharmaceuticals plc per diluted share

      $5.42 - $5.63

      Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc per diluted share

      $9.45 - $9.60



      Weighted-average ordinary shares used in per share computations

      63

      Logo - http://photos.prnewswire.com/prnh/20150930/272253LOGO

      SOURCE Jazz Pharmaceuticals

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.